BridgeMD
New treatment option for Cachexia; Cancer; Sarcopenia
Official title Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics
ClinicalTrials.gov ID: NCT07519837
What this study is testing
What is Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients?
Validation of intervention efficacy through enhanced intervention in nutritionally high-risk patients is an investigational medicine, being studied as a potential treatment for cachexia; cancer; sarcopenia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing "multi-omics" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- Signed informed consent form and voluntary participation in this study
- Histologically and/or cytologically confirmed diagnosis of cancer
- Patients with gastrointestinal malignancies, including:
- Esophageal cancer
You likely can't join if
- Pregnant or lactating women
- Presence of contraindications to surgery
- Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate
- Presence of two or more concurrent primary tumors
See the full eligibility criteria
- Age ≥ 18 years
- Signed informed consent form and voluntary participation in this study
- Histologically and/or cytologically confirmed diagnosis of cancer
- Patients with gastrointestinal malignancies, including:
- Esophageal cancer
- Hepatocellular carcinoma
- Gastric cancer
- Cholangiocarcinoma
- Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy
- Pregnant or lactating women
- Presence of contraindications to surgery
- Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability/unwillingness to cooperate
- Presence of two or more concurrent primary tumors
The study team makes the final eligibility decision.
Where it's taking place
- Shenyang, Liaoning, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shenyang, Liaoning, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.